- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04475510
Seponering av antitrombotisk behandling etter patentert Foramen Ovale-lukking hos unge pasienter med kryptogent hjerneslag (HALTI)
Seponering av antitrombotisk behandling etter patentert Foramen Ovale-lukking hos unge pasienter med kryptogent hjerneslag. HALTI-rettssaken
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Young patients with a cryptogenic ischemic event undergoing transcatheter PFO closure exhibit a low but clinically relevant risk of bleeding (overall and major bleeding) at long-term follow-up, eventually exceeding the risk of ischemic events.
Importantly, the vast majority of major bleeding events seem to occur in patients receiving antiplatelet therapy. Preliminary data suggest that antiplatelet therapy discontinuation is not associated with any increase in ischemic events, and could potentially translate into a lower rate of major bleeding events at longer term follow-up. We therefore hypothesize that in young patients without any other comorbidities increasing the risk of stroke, shorter-term (≤1 year instead of lifelong) antiplatelet treatment could be a safe option following PFO closure.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Melanie Cote, MSc
- Telefonnummer: 14186537270
- E-post: melanie.cote@criucpq.ulaval.ca
Studer Kontakt Backup
- Navn: Josep Rodes-Cabau, MD
- Telefonnummer: 4186568711
- E-post: josep.rodes@criucpq.ulaval.ca
Studiesteder
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Rekruttering
- IUCPQ
-
Ta kontakt med:
- Melanie Cote, MSc
- Telefonnummer: Rodes-Cabau 4186568711
- E-post: josep.rodes@criucpq.ulaval.ca
-
Ta kontakt med:
- Josep Rodes-Cabau, MD
- Telefonnummer: 4186568711
- E-post: josep.rodes@criucpq.ulaval.ca
-
Hovedetterforsker:
- Josep Rodes-Cabau, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Successful transcatheter PFO closure with any approved device
- Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure
Exclusion Criteria:
->60 year-old
- RoPE score <6
- Residual shunt ≥moderate following PFO closure
- Atrial fibrillation following PFO closure
- Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
- Diabetes mellitus
- Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
- Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
- Failure to provide signed informed consent
- Absolute contraindications for an MRI study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Antiplatelet treatment discontinuation
At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Presence of new stroke events
Tidsramme: 12 months
|
1)Acute episode of a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax or other new neurological symptom(s) consistent with stroke.(2)Duration of a focal or global neurological deficit ≥ 24 hours OR < 24 hours if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death. |
12 months
|
|
Presence of new ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of new cerebral ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Volume of new cerebral ischemic lesions
Tidsramme: 24-month follow-up
|
Evaluated by MRI |
24-month follow-up
|
|
Number of ischemic events
Tidsramme: 24-month follow-up
|
Stroke, TIA |
24-month follow-up
|
|
Number of ischemic events
Tidsramme: 3-year follow-up
|
Stroke, TIA |
3-year follow-up
|
|
Number of ischemic events
Tidsramme: 4-year follow-up
|
Stroke, TIA |
4-year follow-up
|
|
Number of ischemic events
Tidsramme: 5-year follow-up
|
Stroke, TIA |
5-year follow-up
|
|
Number of ischemic events
Tidsramme: 6-year follow-up
|
Stroke, TIA |
6-year follow-up
|
|
Number of ischemic events
Tidsramme: 7-year follow-up
|
Stroke, TIA |
7-year follow-up
|
|
Number of ischemic events
Tidsramme: 8-year follow-up
|
Stroke, TIA |
8-year follow-up
|
|
Number of ischemic events
Tidsramme: 9-year follow-up
|
Stroke, TIA |
9-year follow-up
|
|
Number of ischemic events
Tidsramme: 10-year follow-up
|
Stroke, TIA |
10-year follow-up
|
|
Rate of bleeding
Tidsramme: 24-month follow-up
|
Life-threatening, major or minor bleeding |
24-month follow-up
|
|
Rate of bleeding
Tidsramme: 3-year follow-up
|
Life-threatening, major or minor bleeding |
3-year follow-up
|
|
Rate of bleeding
Tidsramme: 4-year follow-up
|
Life-threatening, major or minor bleeding |
4-year follow-up
|
|
Rate of bleeding
Tidsramme: 5-year follow-up
|
Life-threatening, major or minor bleeding |
5-year follow-up
|
|
Rate of bleeding
Tidsramme: 6-year follow-up
|
Life-threatening, major or minor bleeding |
6-year follow-up
|
|
Rate of bleeding
Tidsramme: 7-year follow-up
|
Life-threatening, major or minor bleeding |
7-year follow-up
|
|
Rate of bleeding
Tidsramme: 8-year follow-up
|
Life-threatening, major or minor bleeding |
8-year follow-up
|
|
Rate of bleeding
Tidsramme: 9-year follow-up
|
Life-threatening, major or minor bleeding |
9-year follow-up
|
|
Rate of bleeding
Tidsramme: 10-year follow-up
|
Life-threatening, major or minor bleeding |
10-year follow-up
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Medfødte abnormiteter
- Kardiovaskulære abnormiteter
- Hjertefeil, medfødt
- Slag
- Hjerteseptumdefekter, atrie
- Hjerteseptumdefekter
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Iskemisk hjerneslag
- Blødning
- Foramen Ovale, patent
Andre studie-ID-numre
- HALTI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .